Trial reportEuropean journal of clinical nutrition2014
Palmitic acid in the sn-2 position of dietary triacylglycerols does not affect insulin secretion or glucose homeostasis in healthy men and women.
Trial report in European journal of clinical nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Palmitic Acid Versus Stearic Acid: Effects of Interesterification and Intakes on Cardiometabolic Risk Markers - A Systematic Review.Nutrients · 2020Pooled it
- Intake of Palm Olein and Lipid Status in Healthy Adults: A Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2019Pooled it
- Effects of palm oil consumption on biomarkers of glucose metabolism: A systematic review.PloS one · 2019Pooled it
- Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis.Journal of lipid research · 2018Pooled it
- Interesterified fats rich in palmitic and stearic acids have comparable effects on selected inflammatory related biomarkers.European journal of nutrition · 2026Trial
- The effects of consumption of interesterified fats rich in palmitic acid compared with stearic acid on intermediary markers of cardiometabolic disease risk: a randomized controlled trial in healthy adults.The American journal of clinical nutrition · 2025Trial
- Trial
- Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats-a randomised controlled cross-over trial.European journal of clinical nutrition · 2020Trial
- Interesterified palm olein lowers postprandial glucose-dependent insulinotropic polypeptide response in type 2 diabetes.European journal of nutrition · 2019Trial
- Trial
- Modulation of postprandial lipaemia by a single meal containing a commonly consumed interesterified palmitic acid-rich fat blend compared to a non-interesterified equivalent.European journal of nutrition · 2017Trial
- The effect of different edible oils on body weight: a systematic review and network meta-analysis of randomized controlled trials.BMC nutrition · 2024Article
- Position Statement on Fat Consumption and Cardiovascular Health - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Pediatric Age Palm Oil Consumption.International journal of environmental research and public health · 2018Review
- Effects of dietary palm olein on the cardiovascular risk factors in healthy young adults.Food & nutrition research · 2018Article
- Effects of Plant Oil Interesterified Triacylglycerols on Lipemia and Human Health.International journal of molecular sciences · 2017Review
- Health benefits and evaluation of healthcare cost savings if oils rich in monounsaturated fatty acids were substituted for conventional dietary oils in the United States.Nutrition reviews · 2017Article
- Effects of Lipid Structure Changed by Interesterification on Melting Property and Lipemia.Lipids · 2016Review
- The Increasing Use of Interesterified Lipids in the Food Supply and Their Effects on Health Parameters.Advances in nutrition (Bethesda, Md.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesDietary triacylglycerols containing palmitic acid in the sn-2 position might impair insulin release and increase plasma glucose. SUBJECTS/
methodsWe used a cross-over designed feeding trial in 53 healthy Asian men and women (20-50 years) to test this hypothesis by exchanging 20% energy of palm olein (PO; control) with randomly interesterified PO (IPO) or high oleic acid sunflower oil (HOS). After a 2-week run-in period on PO, participants were fed PO, IPO and HOS for 6 week consecutively in randomly allocated sequences. Fasting (midpoint and endpoint) and postprandial blood at the endpoint following a test meal (3.54 MJ, 14 g protein, 85 g carbohydrate and 50 g fat as PO) were collected for the measurement of C-peptide, insulin, glucose, plasma glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, lipids and apolipoproteins; pre-specified primary and secondary outcomes were postprandial changes in C-peptide and plasma glucose.
resultsLow density lipoprotein cholesterol was 0.3 mmol/l (95% confidence interval (95% CI)) 0.1, 0.5; P<0.001) lower on HOS than on PO or IPO as predicted, indicating good compliance to the dietary intervention. There were no significant differences (P=0.58) between diets among the 10 male and 31 female completers in the incremental area under the curve (0-2 h) for C-peptide in nmol.120 min/l: GM (95% CI) were PO 220 (196, 245), IPO 212 (190, 235) and HOS 224 (204, 244). Plasma glucose was 8% lower at 2 h on IPO vs PO and HOS (both P<0.05).
conclusionPalmitic acid in the sn-2 position does not adversely impair insulin secretion and glucose homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.